Paper35936719
A Network-Guided Approach to Discover Phytochemical-Based Anticancer Therapy: Targeting MARK4 for Hepatocellular Carcinoma.
Ahmed S and 6 others. Front Oncol, 2022. Cited by 20 papers, by iCite.
Cite this record
ConductScience Library. A Network-Guided Approach to Discover Phytochemical-Based Anticancer Therapy: Targeting MARK4 for Hepatocellular Carcinoma. Papers, record 35936719. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35936719
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A Network-Guided Approach to Discover Phytochemical-Based Anticancer Therapy: Targeting MARK4 for Hepatocellular Carcinoma.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References81
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 24092244 | A review on pharmacological and analytical aspects of diosmetin: a concise report. | Chin J Integr Med | 2013 | https://conductscience.org/library/papers/24092244 | PubMed |
| 2 | 29622463 | Genomic and Functional Approaches to Understanding Cancer Aneuploidy. | Cancer Cell | 2018 | https://conductscience.org/library/papers/29622463 | PubMed |
| 3 | 23774734 | Alternative cleavage and polyadenylation: extent, regulation and function. | Nat Rev Genet | 2013 | https://conductscience.org/library/papers/23774734 | PubMed |
| 4 | 21753790 | Advances in sarcoma genomics and new therapeutic targets. | Nat Rev Cancer | 2011 | https://conductscience.org/library/papers/21753790 | PubMed |
| 5 | 29625055 | An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. | Cell | 2018 | https://conductscience.org/library/papers/29625055 | PubMed |
| 6 | 26691984 | Identification of significantly mutated regions across cancer types highlights a rich landscape of functional molecular alterations. | Nat Genet | 2016 | https://conductscience.org/library/papers/26691984 | PubMed |
| 7 | 25230880 | Integrative oncology: really the best of both worlds? | Nat Rev Cancer | 2014 | https://conductscience.org/library/papers/25230880 | PubMed |
| 8 | 24763618 | The structural analysis of MARK4 and the exploration of specific inhibitors for the MARK family: a computational approach to obstruct the role of MARK4 in prostate cancer progression. | Mol Biosyst | 2014 | https://conductscience.org/library/papers/24763618 | PubMed |
| 9 | 19246318 | Global networks of functional coupling in eukaryotes from comprehensive data integration. | Genome Res | 2009 | https://conductscience.org/library/papers/19246318 | PubMed |
| 10 | 16426740 | Cancer: a Systems Biology disease. | Biosystems | 2006 | https://conductscience.org/library/papers/16426740 | PubMed |
| 11 | 38217166 | Lessons from the COVID-19 pandemic for advancing computational drug repurposing strategies. | Nat Comput Sci | 2021 | https://conductscience.org/library/papers/38217166 | PubMed |
| 12 | 24492837 | Cancer Systems Biology: a peek into the future of patient care? | Nat Rev Clin Oncol | 2014 | https://conductscience.org/library/papers/24492837 | PubMed |
| 13 | 28725462 | A differential network analysis approach for lineage specifier prediction in stem cell subpopulations. | NPJ Syst Biol Appl | 2015 | https://conductscience.org/library/papers/28725462 | PubMed |
| 14 | 14594945 | MARK4 is a novel microtubule-associated proteins/microtubule affinity-regulating kinase that binds to the cellular microtubule network and to centrosomes. | J Biol Chem | 2004 | https://conductscience.org/library/papers/14594945 | PubMed |
| 15 | 21376230 | Hallmarks of cancer: the next generation. | Cell | 2011 | https://conductscience.org/library/papers/21376230 | PubMed |
| 16 | 18091723 | A map of human cancer signaling. | Mol Syst Biol | 2007 | https://conductscience.org/library/papers/18091723 | PubMed |
| 17 | 34448628 | Phytoconstituents and Medicinal Plants for Anticancer Drug Discovery: Computational Identification of Potent Inhibitors of PIM1 Kinase. | OMICS | 2021 | https://conductscience.org/library/papers/34448628 | PubMed |
| 18 | 17354233 | Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. | Int J Cancer | 2007 | https://conductscience.org/library/papers/17354233 | PubMed |
| 19 | 33927693 | In-Silico Study of Immune System Associated Genes in Case of Type-2 Diabetes With Insulin Action and Resistance, and/or Obesity. | Front Endocrinol (Lausanne) | 2021 | https://conductscience.org/library/papers/33927693 | PubMed |
| 20 | 24446173 | Cloning, expression, purification and refolding of microtubule affinity-regulating kinase 4 expressed in Escherichia coli. | Appl Biochem Biotechnol | 2014 | https://conductscience.org/library/papers/24446173 | PubMed |
Cited by15
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 20 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39567714 | Deciphering molecular landscape of breast cancer progression and insights from functional genomics and therapeutic explorations followed by in vitro validation. | Sci Rep | 2024 | https://conductscience.org/library/papers/39567714 | PubMed |
| 39480853 | Unlocking vinpocetine's oncostatic potential in early-stage hepatocellular carcinoma: A new approach to oncogenic modulation by a nootropic drug. | PLoS One | 2024 | https://conductscience.org/library/papers/39480853 | PubMed |
| 39342545 | β-Citronellol: a potential anti-inflammatory and gastro-protective agent-mechanistic insights into its modulatory effects on COX-II, 5-LOX, eNOS, and ICAM-1 pathways through in vitro, in vivo, in silico, and network pharmacology studies. | Inflammopharmacology | 2024 | https://conductscience.org/library/papers/39342545 | PubMed |
| 39065790 | Pharmacogenomics: A Genetic Approach to Drug Development and Therapy. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/39065790 | PubMed |
| 39023830 | Resveratrol suppresses liver cancer progression by downregulating AKR1C3: targeting HCC with HSA nanomaterial as a carrier to enhance therapeutic efficacy. | Apoptosis | 2024 | https://conductscience.org/library/papers/39023830 | PubMed |
| 38984575 | Exploring the Mechanism of Shen Qi Gui Oral Liquid against Chemotherapy- Induced Myelosuppression in Cancer Patients Based on Network Pharmacology and Molecular Docking. | Comb Chem High Throughput Screen | 2025 | https://conductscience.org/library/papers/38984575 | PubMed |
| 38911744 | Vanillin-Isatin Hybrid-Induced MARK4 Inhibition As a Promising Therapeutic Strategy against Hepatocellular Carcinoma. | ACS Omega | 2024 | https://conductscience.org/library/papers/38911744 | PubMed |
| 38301049 | Interaction of Sp1 and Setd8 promotes vascular smooth muscle cells apoptosis by activating Mark4 in vascular calcification. | Aging (Albany NY) | 2024 | https://conductscience.org/library/papers/38301049 | PubMed |
| 38054921 | Development and evaluation of a risk score model based on a WNT score gene-associated signature for predicting the clinical outcome and the tumour microenvironment of hepatocellular carcinoma. | Int J Immunopathol Pharmacol | 2023 | https://conductscience.org/library/papers/38054921 | PubMed |
| 38004413 | Cleomin Exerts Acute Antinociceptive Effects in Mice via GABAB and Muscarinic Receptors. | Pharmaceuticals (Basel) | 2023 | https://conductscience.org/library/papers/38004413 | PubMed |
| 36675976 | Role of ZNF143 and Its Association with Gene Expression Patterns, Noncoding Mutations, and the Immune System in Human Breast Cancer. | Life (Basel) | 2022 | https://conductscience.org/library/papers/36675976 | PubMed |
| 36552885 | An Approach for Systems-Level Understanding of Prostate Cancer from High-Throughput Data Integration to Pathway Modeling and Simulation. | Cells | 2022 | https://conductscience.org/library/papers/36552885 | PubMed |
| 36479247 | Genomic profiling and network-level understanding uncover the potential genes and the pathways in hepatocellular carcinoma. | Front Genet | 2022 | https://conductscience.org/library/papers/36479247 | PubMed |
| 36430361 | Transcription Factors as Targets of Natural Compounds in Age-Related Diseases and Cancer: Potential Therapeutic Applications. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36430361 | PubMed |
| 36232319 | Synthesis of Silver Nano Particles Using Myricetin and the In-Vitro Assessment of Anti-Colorectal Cancer Activity: In-Silico Integration. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36232319 | PubMed |
Genes97
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35936719
GET https://conductscience.org/api/papers/v1/35936719/references?page=2